BSE filing, NSE: HINDBIO. Summary written from the filing by ALFA Finder's alert engine.
Hindustan Bio Sciences Ltd: key numbers
- Share price
- ₹6.80
- Market cap
- ₹6.97 Cr
- Revenue (annual)
- ₹0.74 Cr
- Net profit (annual)
- ₹-0.08 Cr
- P/E (TTM)
- -33.8×Sector 46.1×
- Promoter holding
- 12.19%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hindustan Bio Sciences Ltd
All →Hindustan Bio Sciences Board Meeting Date
Hindustan Bio Sciences Ltd intimated a board meeting on October 31, 2026 to consider unaudited financial results for the quarter ended September 30, 2026. The agenda items are proposed only; no results are yet approved.
Hindustan Bio Sciences Other Announcement
Hindustan Bio Sciences Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI Regulation 31(1)(b).
Hindustan Bio Sciences Annual General Meeting
Hindustan Bio Sciences Ltd held its 34th Annual General Meeting on September 30, 2026. The meeting transacted business including adoption of financial statements and capital reduction.
Hindustan Bio Sciences Annual General Meeting
Hindustan Bio Sciences Limited has issued a notice for its 34th Annual General Meeting to be held on September 30, 2026, in Hyderabad.
Hindustan Bio Sciences Annual Report
Hindustan Bio Sciences Ltd submitted its 34th Annual Report for FY 2025-26, containing the AGM notice proposing a scheme of capital reduction.
Hindustan Bio Sciences Board Meeting Date
Hindustan Biosciences scheduled a board meeting for August 31, 2026, to discuss the 34th AGM notice and a proposed scheme of share capital reorganization.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr